Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
暂无分享,去创建一个
[1] J. Peter,et al. Institute for Clinical and Economic Review , 2021, The Right Price.
[2] W. Wong. Economic burden of Alzheimer disease and managed care considerations. , 2020, The American journal of managed care.
[3] B. Winblad,et al. Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework , 2019, Alzheimer's & Dementia.
[4] Wei Xu,et al. Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged ≥65 years , 2018, Alzheimer's & Dementia.
[5] T. Trikalinos,et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.
[6] Sean D Sullivan,et al. Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS. , 2012, Current Alzheimer research.
[7] Paco Martorell,et al. Monetary costs of dementia in the United States. , 2013, The New England journal of medicine.
[8] M. Weinstein,et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. , 1999, Medical care.